





JOINT TRANSNATIONAL CALL 2017: "Translational Research on Rare Cancers"

PARTNER REQUEST/COLLABORATION OFFER

If you would like to have your profile published on the TRANSCAN-2 website, "Looking for a research partner" webpage, please fill out this form and send it to 

If you have any questions about this form, please do not hesitate to contact us at 

Note: Fields marked with a * are mandatory

Contact Information	
First name *	Carmen
Last name *	Balana
Position *	Research Coordinator
Telephone number	+34 93 497 8925
E-mail address*	cbalana@iconcologia.net
Website address	
Institution/Organisation *	Catalan Institute of Oncology/ Badalona
Department*	Medical Oncology
Street	Carretera Canyet sn
Postal Code / City *	08916
Country *	Spain

*** I agree with the publication of my contact data and of this form on the TRANSCAN-2 Website:**

YES



SEARCH FOR A COLLABORATOR

IF YOU ARE LOOKING FOR A PARTNER IN YOUR SUGGESTED PROPOSAL, PLEASE SPECIFY ALSO THE NEEDED EXPERTISE

Project proposal

Shredding the mysteries of glioblastoma

Project title (draft):

Short description of the project in preparation and of the consortium; description of the areas of expertise needed (Max. 2000 words):



OFFER FOR COLLABORATION

IF YOU PROPOSE YOURSELF AS A PARTNER IN A CONSORTIUM, PLEASE DETAIL YOUR EXPERTISE

Short description of the areas of interest and expertise (Max. 2000 words):

We are working on glioblastoma. As a product of a previous grant (Fundació La Marató TV3) we already have the following data/samples/imaging:

Group of study: Patients with glioblastoma treated in six hospitals in Catalonia who received the standard treatment with radiotherapy and concurrent and adjuvant temozolomide between 2004-2014. Anonymised patient data of 432 patients are recorded in an Access database: sex, age, initial symptoms, type and date of surgery, location, type of lesion, KPS, test of the minimal status (MMS), start date of treatment, basal treatment with dexamethasone and anticonvulsants, date of progression, treatment at recurrence and the date of death or loss to follow-up.

Radiology: In addition to the clinical data, pre-operative magnetic resonance imaging (MRI), is available for 301 cases and immediate postoperative MRI is available for 193 cases (183 cases with both available MRI).

Samples: FFPE samples of 328 cases and 20 samples of second surgeries. Tumour samples were preserved in TMA'S for immune-histochemical study (IH) in 278 cases.

Molecular data: MGMT promoter methylation status for 373 cases (167 methylated, 187 no methylated and 19 non-evaluable). Immunohistochemical IDH1 status known for 270 cases (only positive in 10 cases). Other IH studies ongoing. RNA-Seq results of FFPE samples of 151 cases (including 10 second surgeries).

We are looking for projects that help us to better characterize the disease and alternative projects to develop the potential of our data.

